0 480

Cited 9 times in

Comparing the Survival of Two Groups with an Intermediate Clinical Event

DC Field Value Language
dc.contributor.author남정모-
dc.date.accessioned2016-02-19T11:13:25Z-
dc.date.available2016-02-19T11:13:25Z-
dc.date.issued2001-
dc.identifier.issn1380-7870-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/142669-
dc.description.abstractConsider a subject entered on a clinicaltrial in which the major endpoint is a time metric such as deathor time to reach a well defined event. During the observationalperiod the subject may experience an intermediate clinical event.The intermediate clinical event may induce a change in the survivaldistribution. We consider models for the one and two sample problem.The model for the one sample problem enables one to test if theoccurrence of the intermediate event changed the survival distribution.This models provides a way of carrying out non-randomized clinicaltrial to determine if a therapy has benefit. The two sample problemconsiders testing if the probability distributions, with andwithout an intermediate event, are the same. Statistical testsare derived using a semi-Markov or a time dependent mixture model.Simulation studies are carried out to compare these new procedureswith the log rank, stratified log rank and landmark tests. Thenew tests appear to have uniformly greater power than these competitortests. The methods are applied to a randomized clinical trialcarried out by the Aids Clinical Trial Group (ACTG) which comparedlow versus high doses of zidovudine (AZT).-
dc.description.statementOfResponsibilityopen-
dc.format.extent5~19-
dc.relation.isPartOfLIFETIME DATA ANALYSIS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAIDS-Related Opportunistic Infections/complications-
dc.subject.MESHAIDS-Related Opportunistic Infections/drug therapy-
dc.subject.MESHAcquired Immunodeficiency Syndrome/complications-
dc.subject.MESHAcquired Immunodeficiency Syndrome/drug therapy-
dc.subject.MESHAnti-HIV Agents/administration & dosage-
dc.subject.MESHAnti-HIV Agents/therapeutic use-
dc.subject.MESHAntibiotic Prophylaxis-
dc.subject.MESHComputer Simulation-
dc.subject.MESHDose-Response Relationship, Drug-
dc.subject.MESHHIV-1-
dc.subject.MESHHumans-
dc.subject.MESHMarkov Chains-
dc.subject.MESHModels, Statistical*-
dc.subject.MESHPneumocystis-
dc.subject.MESHPneumonia, Pneumocystis/complications-
dc.subject.MESHPneumonia, Pneumocystis/drug therapy-
dc.subject.MESHRandomized Controlled Trials as Topic/methods*-
dc.subject.MESHSurvival Analysis*-
dc.subject.MESHZidovudine/administration & dosage-
dc.subject.MESHZidovudine/therapeutic use-
dc.titleComparing the Survival of Two Groups with an Intermediate Clinical Event-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Preventive Medicine (예방의학)-
dc.contributor.googleauthorChung Mo Nam-
dc.contributor.googleauthorMarvin Zelen-
dc.identifier.doi10.1023/A:1009609925212-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01264-
dc.relation.journalcodeJ02168-
dc.identifier.eissn1572-9249-
dc.identifier.pmid11280847-
dc.identifier.urlhttp://link.springer.com/article/10.1023/A%3A1009609925212-
dc.subject.keywordclinical trials-
dc.subject.keywordintermediate events-
dc.subject.keywordsemi-Markov processes-
dc.subject.keywordscore tests-
dc.subject.keywordzidovudine-
dc.contributor.alternativeNameNam, Jung Mo-
dc.contributor.affiliatedAuthorNam, Jung Mo-
dc.rights.accessRightsnot free-
dc.citation.volume7-
dc.citation.number1-
dc.citation.startPage5-
dc.citation.endPage19-
dc.identifier.bibliographicCitationLIFETIME DATA ANALYSIS, Vol.7(1) : 5-19, 2001-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.